JP2024532882A5 - - Google Patents

Info

Publication number
JP2024532882A5
JP2024532882A5 JP2024512156A JP2024512156A JP2024532882A5 JP 2024532882 A5 JP2024532882 A5 JP 2024532882A5 JP 2024512156 A JP2024512156 A JP 2024512156A JP 2024512156 A JP2024512156 A JP 2024512156A JP 2024532882 A5 JP2024532882 A5 JP 2024532882A5
Authority
JP
Japan
Prior art keywords
amino acid
fusion protein
seq
protein according
variant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024512156A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024532882A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2022/114096 external-priority patent/WO2023025120A1/en
Publication of JP2024532882A publication Critical patent/JP2024532882A/ja
Publication of JP2024532882A5 publication Critical patent/JP2024532882A5/ja
Pending legal-status Critical Current

Links

JP2024512156A 2021-08-24 2022-08-23 Ｇｄｆ１５融合タンパク質及びその使用 Pending JP2024532882A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202110977378 2021-08-24
CN202110977378.7 2021-08-24
PCT/CN2022/114096 WO2023025120A1 (en) 2021-08-24 2022-08-23 Gdf15 fusion proteins and uses thereof

Publications (2)

Publication Number Publication Date
JP2024532882A JP2024532882A (ja) 2024-09-10
JP2024532882A5 true JP2024532882A5 (https=) 2025-08-07

Family

ID=85321545

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024512156A Pending JP2024532882A (ja) 2021-08-24 2022-08-23 Ｇｄｆ１５融合タンパク質及びその使用

Country Status (8)

Country Link
US (3) US20240391971A1 (https=)
EP (3) EP4393940A4 (https=)
JP (1) JP2024532882A (https=)
KR (1) KR20240049337A (https=)
CN (3) CN115925983A (https=)
AU (1) AU2022333099A1 (https=)
CA (1) CA3226178A1 (https=)
WO (3) WO2023025120A1 (https=)

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013537416A (ja) * 2010-08-13 2013-10-03 メディミューン リミテッド 変異型Ｆｃ領域を含むモノマーポリペプチド及び使用方法
EP3683228A3 (en) * 2012-01-26 2020-07-29 Amgen Inc. Growth differentiation factor 15 (gdf-15) polypeptides
US9862752B2 (en) * 2013-07-31 2018-01-09 Amgen Inc. Growth differentiation factor 15 (GDF-15) constructs
CA2919076C (en) * 2013-07-31 2024-01-30 Amgen Inc. Stabilization of fc-containing polypeptides
US10336812B2 (en) * 2016-05-10 2019-07-02 Janssen Biotech, Inc. GDF15 fusion proteins and uses thereof
WO2018166461A1 (en) * 2017-03-14 2018-09-20 Sunshine Lake Pharma Co., Ltd. Dual-target fusion proteins comprising the fc portion of an immunoglobulin
TWI724392B (zh) * 2018-04-06 2021-04-11 美商美國禮來大藥廠 生長分化因子15促效劑化合物及其使用方法
CR20200510A (es) * 2018-04-09 2020-11-26 Amgen Inc Protreínas de fusión del factor de diferenciación de crecimiento 15
US20220002370A1 (en) * 2018-09-27 2022-01-06 Xilio Development, Inc. Masked cytokine polypeptides
SG11202104136YA (en) * 2018-10-23 2021-05-28 Dragonfly Therapeutics Inc Heterodimeric fc-fused proteins
PE20220500A1 (es) * 2019-04-23 2022-04-07 Lg Chemical Ltd POLIPEPTIDO DE FUSION QUE COMPRENDE LA REGION Fc DE INMUNOGLOBULINA Y GDF15
PE20221316A1 (es) * 2019-10-15 2022-09-07 Dragonfly Therapeutics Inc Proteinas que se unen a nkg2d, cd16 y flt3
CA3161302A1 (en) * 2019-11-26 2021-06-03 Yuhan Corporation Long-acting gdf15 fusion protein and pharmaceutical composition comprising same
JP2025504612A (ja) * 2021-12-31 2025-02-13 サンシャイン・レイク・ファーマ・カンパニー・リミテッド Ｇｌｐ－１及びｇｄｆ１５の融合タンパク質並びにその使用

Similar Documents

Publication Publication Date Title
US11229694B2 (en) Vaccine against RSV
CN101010338B (zh) 成纤维细胞生长因子21的突变蛋白
US7622445B2 (en) Muteins of fibroblast growth factor 21
CA3031856C (en) Mg53 mutants, methods of making the same, and uses thereof
UA81897C2 (uk) Гетерологічний пептидильований глюкагон-1-подібний білок та його застосування для для виготовлення лікарського засобу для лікування пацієнтів, що страждають на ожиріння та/або інсулінонезалежний діабет
CN103998462A (zh) Wnt组合物及此类组合物的治疗应用
JP2011528222A5 (https=)
US9474792B2 (en) Method of treating metabolic disorders using PLA2G12A polypeptides and PLA2G12A mutant polypeptides
BRPI0615538A2 (pt) proteìna de fusão, ácido nucléico isolado, vetor, célula hospedeira, método de produção de um polipeptìdio, composição farmacêutica, composição alimentar, método para a redução do peso corpóreo, método para o tratamento de diabetes, método para aumentar a vida média de um peptìdio ou uma proteìna terapêutica recombinante em um indivìduo, método para aumentar a eficácia de um peptìdio ou proteìna terapêutica, método para o tratamento de diabetes ou redução do peso corpóreo
US11746134B2 (en) Human FGF21 mutant with improved effectiveness and stability and pharmaceutical composition thereof
JP2020511425A5 (https=)
JP2024532882A5 (https=)
JP2023516422A (ja) ウリナスタチンポリペプチド
CN1869072A (zh) 与胶原特异结合的神经生长因子及其编码基因与应用
CN1129944A (zh) 新型蛋白质及其制备方法
KR20250148592A (ko) R-스폰딘 단백질의 재조합 변이체 및 그의 용도
HK40051815A (en) Vaccine against rsv comprising modified f polypeptide
CN119285745A (zh) TGF-β受体激动剂多肽及其用途
CN117980323A (zh) R-spondin蛋白的重组变体及其用途
HK1250939B (en) Vaccine against rsv